Several studies have shown that interleukin 6 (IL-6) is a multifunctional cytokine with both
pro-inflammatory and anti-inflammatory activity, depending on the immune response …

Systemic sclerosis (SSc) is a destructive connective tissue disease characterized by
dysregulation of the immune system and fibrosis in the skin and internal organs. The …

Abstract Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder.
Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and …

Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …

Rationale: Tocilizumab, an anti–IL-6 receptor antibody, had no statistically significant effect
on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic …

Interleukin-6 (IL-6) is a proinflammatory cytokine that plays a key role in the pathogenesis
and physiology of inflammatory and autoimmune diseases, such as coronary heart disease …

Introduction Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-
interstitial lung disease (ILD). Here we describe the efficacy and safety of NTD in a real-life …

Background: The American Thoracic Society convened an international multidisciplinary
panel to develop clinical practice guidelines for the treatment of systemic sclerosis …

Systemic sclerosis (SSc), or scleroderma, is a rare, complex, systemic autoimmune disease
of unknown aetiology, characterized by high morbidity and mortality often resulting from …

Objective This phase 3 study was undertaken to investigate the efficacy and safety of
lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous …